Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.68 Billion EUR | 224.23% |
| 2022 | 1.13 Billion EUR | 81.55% |
| 2021 | 625.51 Million EUR | 6.6% |
| 2020 | 586.78 Million EUR | 333.55% |
| 2019 | 135.34 Million EUR | -9.55% |
| 2018 | 149.63 Million EUR | -6.28% |
| 2017 | 159.67 Million EUR | 56.05% |
| 2016 | 102.32 Million EUR | -13.48% |
| 2015 | 118.26 Million EUR | 11.59% |
| 2014 | 105.98 Million EUR | -35.99% |
| 2013 | 165.55 Million EUR | 17.01% |
| 2012 | 141.49 Million EUR | -3.71% |
| 2011 | 146.94 Million EUR | 10.97% |
| 2010 | 132.41 Million EUR | -7.07% |
| 2009 | 142.49 Million EUR | -12.73% |
| 2008 | 163.27 Million EUR | 1.23% |
| 2007 | 161.29 Million EUR | 158.36% |
| 2006 | 62.43 Million EUR | -11.54% |
| 2005 | 70.57 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 2.69 Billion EUR | -2.99% |
| 2024 Q1 | 3.18 Billion EUR | -13.39% |
| 2024 Q2 | 2.91 Billion EUR | -8.46% |
| 2023 Q1 | 1.3 Billion EUR | 15.08% |
| 2023 Q2 | 1.35 Billion EUR | 3.96% |
| 2023 Q3 | 3.79 Billion EUR | 179.26% |
| 2023 Q4 | 3.68 Billion EUR | -2.95% |
| 2023 FY | 3.68 Billion EUR | 224.23% |
| 2022 Q1 | 630.9 Million EUR | 0.86% |
| 2022 FY | 1.13 Billion EUR | 81.55% |
| 2022 Q2 | 732.2 Million EUR | 16.06% |
| 2022 Q3 | 1.16 Billion EUR | 59.19% |
| 2022 Q4 | 1.13 Billion EUR | -2.57% |
| 2021 Q3 | 643.1 Million EUR | 5.44% |
| 2021 Q4 | 625.51 Million EUR | -2.73% |
| 2021 FY | 625.51 Million EUR | 6.6% |
| 2021 Q1 | 609.2 Million EUR | 3.82% |
| 2021 Q2 | 609.9 Million EUR | 0.11% |
| 2020 Q2 | 332.6 Million EUR | 186.48% |
| 2020 Q1 | 116.1 Million EUR | -14.22% |
| 2020 FY | 586.78 Million EUR | 333.55% |
| 2020 Q4 | 586.78 Million EUR | 77.49% |
| 2020 Q3 | 330.6 Million EUR | -0.6% |
| 2019 Q4 | 135.34 Million EUR | -4.15% |
| 2019 FY | 135.34 Million EUR | -9.55% |
| 2019 Q2 | 170.8 Million EUR | 23.23% |
| 2019 Q3 | 141.2 Million EUR | -17.33% |
| 2019 Q1 | 138.6 Million EUR | -7.37% |
| 2018 Q3 | 194.6 Million EUR | 6.46% |
| 2018 Q1 | 159.5 Million EUR | -0.11% |
| 2018 Q4 | 149.63 Million EUR | -23.11% |
| 2018 FY | 149.63 Million EUR | -6.28% |
| 2018 Q2 | 182.8 Million EUR | 14.61% |
| 2017 Q4 | 159.67 Million EUR | -10.35% |
| 2017 FY | 159.67 Million EUR | 56.05% |
| 2017 Q1 | 172.8 Million EUR | 71.55% |
| 2017 Q2 | 199.8 Million EUR | 15.63% |
| 2017 Q3 | 178.1 Million EUR | -10.86% |
| 2016 FY | 102.32 Million EUR | -13.48% |
| 2016 Q3 | 128.2 Million EUR | -12.85% |
| 2016 Q2 | 147.1 Million EUR | 34.95% |
| 2016 Q1 | 109 Million EUR | -6.64% |
| 2016 Q4 | 100.73 Million EUR | -21.43% |
| 2015 Q4 | 116.75 Million EUR | -11.28% |
| 2015 Q3 | 131.6 Million EUR | -6.47% |
| 2015 Q2 | 140.7 Million EUR | 25.18% |
| 2015 Q1 | 112.4 Million EUR | 7.65% |
| 2015 FY | 118.26 Million EUR | 11.59% |
| 2014 FY | 105.98 Million EUR | -35.99% |
| 2014 Q4 | 104.41 Million EUR | -36.57% |
| 2014 Q3 | 164.6 Million EUR | -6.0% |
| 2014 Q2 | 175.1 Million EUR | -5.09% |
| 2014 Q1 | 184.5 Million EUR | 10.5% |
| 2013 FY | 165.55 Million EUR | 17.01% |
| 2013 Q4 | 166.96 Million EUR | 21.69% |
| 2013 Q2 | 168.2 Million EUR | 0.0% |
| 2013 Q3 | 137.2 Million EUR | -18.43% |
| 2012 FY | 141.49 Million EUR | -3.71% |
| 2012 Q2 | 186.9 Million EUR | 0.0% |
| 2011 Q2 | 154.7 Million EUR | 0.0% |
| 2011 FY | 146.94 Million EUR | 10.97% |
| 2010 Q2 | 154.1 Million EUR | 0.0% |
| 2010 FY | 132.41 Million EUR | -7.07% |
| 2009 FY | 142.49 Million EUR | -12.73% |
| 2009 Q4 | 142.49 Million EUR | 0.0% |
| 2008 FY | 163.27 Million EUR | 1.23% |
| 2007 FY | 161.29 Million EUR | 158.36% |
| 2006 FY | 62.43 Million EUR | -11.54% |
| 2005 FY | 70.57 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 500 Thousand USD | -736280.0% |
| Ansell Limited | 855.59 Million USD | -330.332% |
| Ansell Limited | 857.2 Million USD | -329.526% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 22.41 Million USD | -16328.573% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 20.93 Thousand USD | -17587194.005% |
| Psykey, Inc. | 1.01 Million USD | -364228.122% |
| ConvaTec Group Plc | 1.31 Billion USD | -180.944% |
| ConvaTec Group Plc | 1.31 Billion USD | -180.547% |
| Encision Inc. | 1.33 Million USD | -276069.703% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | -159378.186% |
| Innovative MedTech Inc. | 1.87 Million USD | -195930.827% |
| LifePoint, Inc. | 446.74 Thousand USD | -824070.659% |
| Medite Cancer Diagnostics, Inc. | 5.39 Million USD | -68156.874% |
| Paradigm Medical Industries, Inc. | 2.18 Million USD | -168100.091% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | - USD | -Infinity% |
| Reflect Scientific, Inc. | 242.64 Thousand USD | -1517308.219% |
| SmileDirectClub, Inc. | 871.79 Million USD | -322.335% |
| Sector 10, Inc. | 164 Thousand USD | -2244960.976% |
| Shandong Weigao Group Medical Polymer Company Limited | 674.01 Million USD | -446.266% |
| SheerVision, Inc. | 75 Thousand USD | -4909100.0% |
| United Health Products, Inc. | 755.98 Thousand USD | -486930.896% |
| Vasamed, Inc. | 23.45 Thousand USD | -15700966.098% |
| Wearable Health Solutions, Inc. | 2.76 Million USD | -132946.9% |
| Yubo International Biotech Limited | 790.49 Thousand USD | -465669.09% |